Infraredx is a cardiovascular imaging company pioneering the personalized diagnosis of coronary artery disease, the world's leading cause of death according to the World Health Organization. Infraredx is committed to assisting in the optimization of coronary stenting procedures and post-stenting management, and believes that its technology may ultimately serve as part of a strategy to provide secondary and eventually primary prevention of coronary events.

Infraredx has the distinction of being the only company with an intravascular imaging system that is FDA-cleared for the detection of lipid core plaques, which are known to complicate stenting.

Since its founding in 1999, Infraredx has leveraged major advances in lasers and optics to develop intelligent catheter-based coronary imaging devices.